• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    MyMD Pharmaceuticals Announces Reverse Stock Split to Maintain Nasdaq Listing

    2/13/24 11:45:00 AM ET
    $MYMD
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Get the next $MYMD alert in real time by email

    Common Stock Will Begin Trading on Split-Adjusted Basis on February 15, 2024

    MyMD Pharmaceuticals, Inc.® (NASDAQ:MYMD) ("MyMD" or "the Company"), a clinical stage biopharmaceutical company committed to developing novel therapies for age-related diseases, autoimmune and inflammatory conditions, announced today that it intends to effect a reverse stock split of its common stock at a ratio of 1 post-split share for every 30 pre-split shares. The reverse stock split will become effective at 4:05 p.m. Eastern Standard Time on Wednesday, February 14, 2024. MyMD's common stock will continue to be traded on the Nasdaq Capital Market under the symbol MYMD and will begin trading on a split-adjusted basis when the market opens on Thursday, February 15, 2024. The new CUSIP number for MyMD's common stock following the reverse stock split will be 62856X201.

    At the effective time of the reverse stock split, every 30 shares of MyMD's issued and outstanding common stock will be converted automatically into one issued and outstanding share of common stock without any change in the par value per share. Simultaneously therewith, the number of shares of common stock that the Company shall have authority to issue will be reduced by a factor of 30 from 500,000,000 shares to 16,666,666 shares. Stockholders holding shares through a brokerage account will have their shares automatically adjusted to reflect the 1‑for-30 reverse stock split. It is not necessary for stockholders holding shares of the Company's common stock in certificated form to exchange their existing stock certificates for new stock certificates of the Company in connection with the reverse stock split, although stockholders may do so if they wish.

    The reverse stock split will affect all stockholders uniformly and will not alter any stockholder's percentage interest in the Company's equity, except to the extent that the reverse stock split would result in a stockholder owning a fractional share. Any fractional share of a stockholder resulting from the reverse stock split will be rounded up to the nearest whole number of shares. The reverse stock split will reduce the number of shares of MyMD's common stock outstanding from 62,749,125 shares to approximately 2,091,638 shares, subject to adjustment for the rounding up of fractional shares. Proportional adjustments will be made to the number of shares of MyMD's common stock issuable upon exercise or conversion of MyMD's equity awards, convertible preferred stock and warrants, as well as the applicable exercise or conversion price. Stockholders with shares in brokerage accounts should direct any questions concerning the reverse stock split to their broker; all other stockholders may direct questions to the Company's transfer agent, Securities Transfer Corporation, via email at [email protected] or phone at (469) 633-0101.

    About MyMD Pharmaceuticals, Inc.

    MyMD Pharmaceuticals, Inc. (NASDAQ:MYMD), a clinical stage pharmaceutical company committed to extending healthy lifespan, is focused on developing two novel therapeutic platforms that treat the causes of disease rather than only addressing the symptoms. MYMD-1 is a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-α, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. MYMD-1 is being developed to delay aging, increase longevity, and treat autoimmune diseases. The Company's second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction and epilepsy. Supera-CBD is a novel synthetic derivative of cannabidiol (CBD) and is being developed to address and improve upon the rapidly growing CBD market, which includes both FDA approved drugs and CBD products not currently regulated as drugs. For more information, visit www.mymd.com.

    Cautionary Statement Regarding Forward-Looking Statements

    This press release may contain forward-looking statements. These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause actual results, performance or achievements to be materially different from any expected future results, performance, or achievements. Forward-looking statements speak only as of the date they are made and none of MyMD nor its affiliates assume any duty to update forward-looking statements. Words such as "anticipate," "believe," "could," "estimate," "expect," "may," "plan," "will," "would'' and other similar expressions are intended to identify these forward-looking statements. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include, without limitation: the effect that the reverse stock split may have on the price of MyMD's common stock; MyMD's ability to regain and maintain compliance with the Nasdaq Stock Market's listing standards; the timing of, and MyMD's ability to, obtain and maintain regulatory approvals for clinical trials of MyMD's pharmaceutical candidates; the timing and results of MyMD's planned clinical trials for its pharmaceutical candidates; the amount of funds MyMD requires for its pharmaceutical candidates; increased levels of competition; changes in political, economic or regulatory conditions generally and in the markets in which MyMD operates; MyMD's ability to retain and attract senior management and other key employees; MyMD's ability to quickly and effectively respond to new technological developments; MyMD's ability to protect its trade secrets or other proprietary rights, operate without infringing upon the proprietary rights of others and prevent others from infringing on MyMD's proprietary rights; and the impact of the ongoing COVID-19 pandemic on MyMD's results of operations, business plan and the global economy. A discussion of these and other factors with respect to MyMD is set forth in the Company's Annual Report on Form 10-K for the year ended December 31, 2022, filed by MyMD on March 31, 2023. Forward-looking statements speak only as of the date they are made and MyMD disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20240213384915/en/

    Get the next $MYMD alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $MYMD

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $MYMD
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • TNF Pharmaceuticals (Formerly MyMD Pharmaceuticals) Begins Trading Under New Nasdaq Stock Symbol "TNFA" Effective Before Market Open Today

      New name and stock symbol represents therapeutic focus on inhibiting TNF-alpha to regulate the immuno-metabolic system TNF Pharmaceuticals, Inc. (NASDAQ:TNFA) (formerly MyMD Pharmaceuticals, Inc.) (the "Company"), a clinical stage biopharmaceutical company committed to developing novel therapies for age-related diseases and autoimmune and inflammatory conditions, today announced that its common stock, listed on the Nasdaq Capital Market, begins trading under the new ticker symbol, "TNFA," effective before the market open today, July 24, 2024. The new trading symbol "TNFA" replaces the Company's previous trading symbol "MYMD" and coincides with the Company's previously announced corporat

      7/24/24 9:05:00 AM ET
      $MYMD
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • MyMD Pharmaceuticals Announces Corporate Rebranding to New Name TNF Pharmaceuticals, Inc.

      New name represents therapeutic focus on inhibiting TNF-alpha to regulate the immuno-metabolic system Company plans mid-stage clinical trials of TNF-alpha inhibitor drug MYMD-1® following statistically significant Phase 2 studies TNF Pharmaceuticals will begin trading on Nasdaq under the new trading symbol "TNFA" effective July 24, 2024 TNF Pharmaceuticals, Inc., formerly MyMD Pharmaceuticals, Inc. (NASDAQ:MYMD) (the "Company"), a clinical stage biopharmaceutical company committed to developing novel therapies for age-related diseases and autoimmune and inflammatory conditions, today announced a rebranding to the new name "TNF Pharmaceuticals, Inc.," effective today. The Company's com

      7/22/24 9:00:00 AM ET
      $MYMD
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • MyMD Pharmaceuticals Appoints Accomplished Biopharmaceutical Leader and Current Board Member, Mitchell Glass, M.D. as President and Chief Medical Officer

      Dr. Glass brings a 35-year career in life sciences with multiple drug approvals including Accolate ®, Avandia ® and Coreg® Dr. Glass brings broad expertise in regulatory strategies: 5 NDAs and MAAs, 7 pre-NDA meetings, 12 End of Phase 2 meetings, and more than 80 INDs Company announces President and CMO transition as clinical development advances through mid-stage trials Company also appoints new independent board member, Mr. Stephen Friscia, an experienced investment strategist MyMD Pharmaceuticals, Inc. (NASDAQ:MYMD) ("MyMD" or the "Company"), a clinical stage biopharmaceutical company committed to developing novel therapies for age-related diseases and autoimmune and inflamm

      6/17/24 9:00:00 AM ET
      $MYMD
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $MYMD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 3 filed by new insider Friscia Stephen

      3 - MyMD Pharmaceuticals, Inc. (0001321834) (Issuer)

      6/28/24 4:05:18 PM ET
      $MYMD
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form 3 filed by new insider Pharmacyte Biotech, Inc.

      3 - MyMD Pharmaceuticals, Inc. (0001321834) (Issuer)

      5/30/24 4:05:04 PM ET
      $MYMD
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form 3 filed by new insider Glass Mitchell

      3 - MyMD Pharmaceuticals, Inc. (0001321834) (Issuer)

      5/16/24 5:30:25 PM ET
      $MYMD
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $MYMD
    SEC Filings

    See more
    • SEC Form DEF 14A filed by MyMD Pharmaceuticals Inc.

      DEF 14A - MyMD Pharmaceuticals, Inc. (0001321834) (Filer)

      7/1/24 5:15:16 PM ET
      $MYMD
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • MyMD Pharmaceuticals Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

      8-K - MyMD Pharmaceuticals, Inc. (0001321834) (Filer)

      6/24/24 4:23:01 PM ET
      $MYMD
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form S-3 filed by MyMD Pharmaceuticals Inc.

      S-3 - MyMD Pharmaceuticals, Inc. (0001321834) (Filer)

      6/21/24 5:14:29 PM ET
      $MYMD
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $MYMD
    Leadership Updates

    Live Leadership Updates

    See more
    • MyMD Pharmaceuticals Appoints Accomplished Biopharmaceutical Leader and Current Board Member, Mitchell Glass, M.D. as President and Chief Medical Officer

      Dr. Glass brings a 35-year career in life sciences with multiple drug approvals including Accolate ®, Avandia ® and Coreg® Dr. Glass brings broad expertise in regulatory strategies: 5 NDAs and MAAs, 7 pre-NDA meetings, 12 End of Phase 2 meetings, and more than 80 INDs Company announces President and CMO transition as clinical development advances through mid-stage trials Company also appoints new independent board member, Mr. Stephen Friscia, an experienced investment strategist MyMD Pharmaceuticals, Inc. (NASDAQ:MYMD) ("MyMD" or the "Company"), a clinical stage biopharmaceutical company committed to developing novel therapies for age-related diseases and autoimmune and inflamm

      6/17/24 9:00:00 AM ET
      $MYMD
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • MyMD Pharmaceuticals Appoints David Rini, Professor at the Johns Hopkins School of Medicine, to Scientific Advisory Board

      MyMD Pharmaceuticals, Inc. (NASDAQ:MYMD), a clinical stage pharmaceutical company committed to extending healthy lifespan by focusing on developing two therapeutic platforms, announced today that it has appointed David Rini to the Company's Scientific Advisory Board. "I am delighted to join the MyMD Scientific Advisory Board and look forward to working on the development and communication about our two platforms," stated David Rini. David Rini is a Professor at the Johns Hopkins University School of Medicine in the Department of Art of Applied to Medicine, Cellular and Molecular Medicine, and Director of the Medical and Biological Illustration Graduate Program. Professor Rini earned his M

      5/17/21 9:00:00 AM ET
      $MYMD
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $MYMD
    Financials

    Live finance-specific insights

    See more
    • MyMD Pharmaceuticals to Hold Conference Call Today to Discuss Phase 2 Trial Results

      MyMD Pharmaceuticals, Inc.® (NASDAQ:MYMD) ("MyMD" or the "Company"), a clinical stage pharmaceutical company committed to developing novel therapies for age-related diseases, autoimmune and inflammatory conditions, announced statistically significant positive topline Phase 2 results for its next generation Oral TNF-α inhibitor MYMD-1 in Sarcopenia/Age-Related Frailty earlier this week. In conjunction with its release, the company also announced it will hold a conference call today, August 2nd, at 4:30pm ET to discuss the results. To participate in the conference call, please register here. A webcast can also be accessed under the ‘Events & Presentations' section on the Investors page at w

      8/2/23 8:30:00 AM ET
      $MYMD
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • MyMD Pharmaceuticals Reports Statistically Significant Positive Topline Phase 2 Results for Next Generation Oral TNF-α Inhibitor MYMD-1® in Sarcopenia/Age-Related Frailty

      - MYMD-1 significantly reduced serum levels of chronic inflammatory markers and met all primary pharmacokinetic and secondary safety and tolerability endpoints across multiple doses over 28 days of treatment - MYMD-1 demonstrated statistical significance across three biomarkers: TNF-α (P=0.008), sTNFR1 (P=0.02), and IL-6 (P=0.03) - First Oral TNF-α inhibitor, if approved, would offer potential patient benefit in large markets - Company to present the data to FDA and intends to advance the clinical program for MYMD-1; will hold conference call on August 2, 2023, at 4:30 PM Eastern Time MyMD Pharmaceuticals, Inc.® (NASDAQ:MYMD) ("MyMD" or the "Company"), a clinical stage pharmaceutica

      7/31/23 9:00:00 AM ET
      $MYMD
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $MYMD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D filed by MyMD Pharmaceuticals Inc.

      SC 13D - MyMD Pharmaceuticals, Inc. (0001321834) (Subject)

      5/30/24 4:05:03 PM ET
      $MYMD
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form SC 13G filed by MyMD Pharmaceuticals Inc.

      SC 13G - MyMD Pharmaceuticals, Inc. (0001321834) (Subject)

      2/14/24 3:13:35 PM ET
      $MYMD
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form SC 13G/A filed by MyMD Pharmaceuticals Inc. (Amendment)

      SC 13G/A - MyMD Pharmaceuticals, Inc. (0001321834) (Subject)

      2/14/24 11:27:33 AM ET
      $MYMD
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care